Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Janssen Pharmaceutical Cos.

Division of Johnson & Johnson
www.janssen.com

Latest From Janssen Pharmaceutical Cos.

Finance Watch: Moderna Capitalizes On COVID-19 Vaccine Data Value Boost

Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.

Financing Business Strategies

ASCO 2020: BCMA CAR-T Race Heats Up Between Bristol And Janssen

The gap between potential approvals for Bristol’s ide-cel and Janssen’s JNJ-4528 has narrowed as both CAR-T therapies show high response rates in multiple myeloma – and as bispecific antibodies, including Janssen’s teclistamab, edge into the space.

ASCO ImmunoOncology

Start-Up Quarterly Statistics, Q1 2020

A review of biopharma start-up dealmaking and financing activity from January through March 2020, based on data from Biomedtracker.

Deals Financing

Crunch Time At EMA For Luspatercept And Glasdegib

Eight new marketing applications including ones from BMS/Acceleron Pharma and Pfizer are up for an opinion at the April meeting of the European Medicines Agency’s drug evaluation committee, the CHMP.

Drug Review Europe
See All

Company Information

UsernamePublicRestriction

Register